CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment and up to $300 million in total milestones, including $16 million in clinical milestones and $44 million in regulatory milestones for the first indication. CrystalGenomics is also eligible for single-digit royalties. ...